KD-370 is under clinical development by KM Biologics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect KD-370’s likelihood of approval (LoA) and phase transition for Haemophilus influenzae Type B Infections took place on 14 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 14 Nov 2022 decreased KD-370’s LoA and PTSR for Pertussis (Whooping Cough).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their KD-370 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
KD-370 is under development for the prevention of diphtheria, pertussis, poliomyelitis, tetanus and Haemophilus influenzae type B infections. The vaccine candidate is a pentavalent vaccine administered through subcutaneous and intramuscular routes.
KM Biologics overview
KM Biologics (KMB) develops pharmaceuticals and veterinary vaccines to prevent infections and improving public health. The company’s products include antitoxins and antivenoms, and blood plasma products. KMB is headquartered in Kumamoto, Kyoto, Japan.
Quick View KD-370 LOA Data
|Highest Development Stage|